key: cord-0880379-zun2id7u
authors: López Montesinos, Inmaculada; Arrieta-Aldea, Itziar; Dicastillo, Aitor; Zuccarino, Flavio; Sorli, Luisa; Guerri-Fernández, Roberto; Arnau-Barrés, Isabel; Milagro Montero, Maria; Siverio-Parès, Ana; Durán, Xavier; del Mar Arenas, Maria; Brasé Arnau, Ariadna; Cañas-Ruano, Esperanza; Castañeda, Silvia; Domingo Kamber, Ignacio; Gómez-Junyent, Joan; Pelegrín, Iván; Sánchez Martínez, Francisca; Sendra, Elena; Suaya Leiro, Lucía; Villar-García, Judit; Nogués, Xavier; Grau, Santiago; Knobel, Hernando; Gomez-Zorrilla, Silvia; Pablo Horcajada, Juan
title: Comparison of hospitalized COVID-19 and influenza patients requiring supplemental oxygen in a cohort study: clinical impact and resource consumption
date: 2022-04-20
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac314
sha: 49a9911b1581b06b0f88c29059376738d3ff269a
doc_id: 880379
cord_uid: zun2id7u

BACKGROUND: To compare clinical characteristics, outcomes, and resource consumption of patients with COVID-19 and seasonal influenza requiring supplemental oxygen. METHODS: Retrospective cohort study conducted at a tertiary-care hospital. Patients admitted due to seasonal influenza between 2017 and 2019, or with COVID-19 between March and May 2020 requiring supplemental oxygen were compared. Primary outcome: 30-day mortality. Secondary outcomes: 90-day mortality and hospitalization costs. Attempted sample size to detect an 11% difference in mortality was 187 patients per group. RESULTS: COVID-19 cases were younger (median years, 67 (IQR 54-78) vs 76 (IQR 64-83); p < 0.001) and more frequently overweight whereas influenza cases had more hypertension, immunosuppression, and chronic heart, respiratory and renal disease. Compared to influenza, COVID-19 cases had more pneumonia (98% vs 60%, <0.001), higher MEWS and CURB-65 scores and were more likely to show worse progression on the WHO ordinal scale (33% vs 4%; p < 0.001). The 30-day mortality rate was higher for COVID-19 than for influenza: 15% vs 5% (p = 0.001). The median age of non-surviving cases was 81 (IQR 74-88) and 77.5 (IQR 65-84) (p = 0.385), respectively. COVID-19 was independently associated with 30-day (HR 4.6, 95%CI, 2-10.4) and 90-day (HR 5.2, 95%CI, 2.4-11.4) mortality. Sensitivity and subgroup analyses, including a subgroup considering only patients with pneumonia, did not show different trends. Regarding resource consumption, COVID-19 patients had longer hospital stays and higher critical care, pharmacy, and complementary test costs. CONCLUSIONS: Although influenza patients were older and had more comorbidities, COVID-19 cases requiring supplemental oxygen on admission had worse clinical and economic outcomes.

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] , the coronavirus disease 2019 (COVID-19) has been compared to influenza virus. Both viruses are similar in symptoms, transmission routes, and risk groups.

Clinical presentation ranges from asymptomatic to critical cases, although most infections are not severe [2,3]. Among hospitalized patients however, the proportion of critical disease is higher, ranging from 3% to 20% for influenza, and from 14% to 50% for COVID-19 [4] [5] [6] [7] [8] .

Both viruses can cause severe illness in otherwise healthy individuals, but elderly or comorbid patients are at highest risk of severe influenza illness [9] . In COVID-19, age plays a major role in outcome [10] .

In terms of resource consumption, prior data show that seasonal influenza places a strain on the healthcare system [9] . However, the SARS-CoV-2 pandemic is a historic public health crisis, requiring unprecedented allocations of medical resources to ensure patient care and prevent health system collapse.

We hypothesized that adults with SARS-COV-2 requiring oxygen at admission have worse outcomes and consume more resources than those with influenza. Prior studies [4] [5] [6] [7] [8] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] have compared characteristics and/or outcomes of both diseases. To our knowledge, this is the first study to assess only patients requiring supplemental oxygen at admission. More relaxed admission criteria due to concerns about the novel SARS-COV-2 may have led to hospitalization of fewer sick people with COVID-19. Thus, considering only admitted patients requiring oxygen may provide a more objective selection criterion.

Furthermore, although some cohorts [4] [5] [6] [7] [8] 16, 18, 20] have explored resource consumption, none have detailed the burden of disease on hospitalization costs.

This study aims to compare the clinical characteristics, mortality and resource consumption of patients hospitalized for COVID-19 or influenza requiring supplemental oxygen.

A retrospective observational cohort study performed at the Hospital del Mar, a tertiary university hospital in Barcelona (Spain). ('first wave') were included. Patients were included consecutively, starting from the initial date of the study period until the required sample size was reached.

Patients were followed for 90 days from the date of the positive test, using the regional electronic healthcare records (integrating hospital, primary care, and long-term facilities).

Patients whose mortality could not be assessed due to lack of records during the follow-up period were considered lost to follow-up and excluded. Hospital-acquired infections were excluded to avoid overestimating hospitalization costs and length of stay accounted for before the COVID-19 or influenza episode. The Clinical Research Ethical Committee of Parc Salut Mar approved this study (registration no. 2021/9892). Written informed consent was waived due to its observational and retrospective nature.

The primary endpoint was all-cause 30-day mortality. Secondary endpoints were 90-day mortality and hospitalization costs.

Demographic, clinical, and epidemiological data were collected from electronic records.

Influenza and pneumococcal vaccination status was ascertained through primary care records.

Patients with no official vaccination record were considered "not vaccinated". Severity of underlying diseases were assessed by Charlson comorbidity index [23] . Immunosuppression was defined as malignancy, untreated HIV and/or CD4 count <200 cells/µl, pregnancy, inflammatory and autoimmune disorders, transplant or other diseases under immunosuppressive agents, corticosteroid therapy, defined as 10 mg of oral prednisone or equivalent for a month, poorly controlled diabetes mellitus, defined as HbA1c>9% with target organ damage, and/or primary immune deficiency disease.

Also recorded were signs and symptoms at admission, time from symptom onset to hospital admission, laboratory test parameters, baseline chest X-ray findings, treatment received, need for intensive care unit (ICU) admission, and respiratory support. Chest X-rays were classified into 2 groups: those with new radiographic findings consistent with acute pneumonia (groundglass, linear opacities, or consolidations), and those normal or showing non-acute findings Complications developing during hospitalization (pulmonary embolism, secondary infections, heart failure, atrial fibrillation, acute kidney injury) were recorded.

Variables studied for healthcare resource consumption included: length of stay, days in ICU, days of respiratory support, readmissions, and overall hospitalization, pharmaceutical, laboratory, imaging, and other diagnostic procedure costs.

Determination of the sample size (187 patients per group) to detect at least an 11% difference in mortality between groups was based on previous results [4]. Statistical power was set at 0.8, alpha error 0.05, and estimated loss to follow-up 0.3.

Continuous quantitative variables were presented as median and interquartile range (IQR), categorical variables as numbers and percentages. Categorical variables were compared by χ2 test or Fisher's exact test, and continuous variables by the Student's t-test or Mann-Whitney Utest, as appropriate.

The Kaplan-Meier estimator estimated time-until-death. The log-rank test compared the risk of death between study groups. Receiver Operating Characteristic (ROC) curves were used to identify the optimal cutoff age for prediction of 30-and 90-day mortality, and Youden's criterion to determine optimal cutoff points: the sample point maximizing the Youden Index (sensitivity+specificity-1).

Cox proportional hazards was used to perform multivariate survival analyses of 30-and 90-day mortality, with hazard ratios (HR) and 95% confidence intervals (CI). Variables with p value ≤.2 were included in the initial model, together with variables not statistically significant but clinically relevant. Corticosteroid therapy and pneumonia were considered clinically relevant and forced into models. Baseline MEWS score and PaO2/FiO2 ratio were included to adjust for severity.

Complications during hospitalization were considered intermediate variables between exposure and death and were not included. Cox models were built using backward stepwise selection.

Variance inflation factors were used to detect collinearity between variables in the models. The proportional hazards assumption was tested. Variables with > 25% missing values were not considered.

Sensitivity analyses were performed to investigate the impact of COVID-19 versus influenza on 30-and 90-day mortality in subgroups of interest (age <74 or ≥74-years; including only noninfluenza vaccinated patients and those with pneumonia and/or bilateral involvement).

Economic impact was evaluated by median regression to deal with lack of normality of dependent variables (hospitalization costs). Results were expressed as difference of medians.

Interpretation of coefficients, as in multiple linear regression, was based on differences of means.

All p-values were 2-tailed and statistical significance was <0.05. Statistical analyses were performed using STATA 15.1. STROBE guidelines were used to report the study (Supplementary Table S1 ).

Overall, 614 COVID-19 patients and 411 influenza patients were admitted during the study period. Based on the attempted sample size, 187 patients were included per group (Figure 1 ).

Differences in baseline characteristics, clinical presentation, complementary tests, complications, and therapeutic management between groups are shown in table 1. The most frequent subtype viruses were influenza A H1N1 (65%) and B (26.74%).

COVID-19 patients were younger than those with influenza and had fewer underlying diseases.

Overall, influenza cases had worse abnormal blood count values, excluding ferritin and hepatic enzyme levels. Pneumonia was seen more in COVID-19 than influenza patients (98% vs 59%; p<0.001). Among influenza cases with no pneumonia (n=77), 41 (53%) had radiological changes secondary to chronic pneumopathy and clinical signs of acute exacerbation, 19 (25%) pulmonary edema, and 17 (22%) had normal x-rays but wheezing and/or rales on examination.

More than 86% of these 77 patients reported influenza systemic symptoms.

COVID-19 patients presented higher MEWS and CURB-65 scores at baseline, but mild ARDS was more frequent in influenza cases (66% vs 50%; p=0.022). Evolution of patient status on the WHO ordinal scale during admission is shown in Figure 2 .

58% of patients received virus-targeting agents. Nearly all influenza cases (98%) received oseltamivir. COVID-19 patients were given lopinavir/ritonavir (17%) and remdesivir (1%).

Overall, more than 90% of patients received concomitant antibiotic therapy. The most frequent

regimen in the COVID-19 group was ceftriaxone plus azithromycin (72%) versus amoxicillin/clavulanate (30%) and levofloxacin (21%) in influenza group.

Concomitant bacterial pneumonia at admission was more frequent in influenza than COVID-19 cases (n=39/43, 90.7% vs n=8/27, 29.6%, p<0.001). Streptococcus pneumoniae was the leading microorganism (26 and 4 episodes, respectively). Hospital-acquired pneumonia was more seen in COVID-19 (n=19/27, 70.4%) than influenza group (n=4/43, 9.3%) and

Pseudomonas aeruginosa was the most frequent microorganism (n=8 and n=2 patients, respectively). Patients with COVID-19 were more likely to have hospital-acquired infections other than pneumonia (20% vs 3%, p<0.001) and to develop bacteremia (14% vs 4%, p=0.001).

30-day mortality was 15% (n=29/187) in COVID-19 and 5% (n=10/187) in influenza (HR 3.07, 95%CI, 1.5-6.31). Median age was 81 years (IQR 74-88) in COVID-19 and 77.5 years (IQR 65-84) in influenza (p=0.385). 70% of influenza deaths were caused by influenza A subtype H1N1. 90-day mortality was 19% (n=35/187) in COVID-19 and 6% (n=12/187) in influenza (HR 3.12, 95%CI, 1.62-6.02). Median age was 78 (IQR 72-87) in COVID-19, and 77.5 (IQR 64-84.5) in influenza (p=0.558). Influenza A subtype H1N1 (67%) and influenza B (25%) were the most common subtypes in non-surviving influenza patients.

There were no differences in mortality trends between the three periods of seasonal influenza studied. Figure 3A shows Kaplan-Meier curves for 30-day mortality by infection group. Based on ROC curve analysis, the optimal cutoff age for predicting mortality was 74 years ( Figure S1 Univariate and multivariate analyses of 30-day mortality are shown in Table 2 . COVID-19 was an independent risk factor for 30-day mortality. Data of 90-day mortality are shown in supplementary material (Table S2 and Figure S2 ). Similarly, COVID-19 was also associated with higher 90-day mortality.

Subgroup and sensitivity analyses of the impact of COVID-19 versus influenza on 30-and 90day mortality in subgroups of interest are shown in supplementary table S3. COVID-19 was also associated with higher 30-and 90-day mortality considering only patients with pneumonia (Table 3 and supplementary table S4 , respectively) and non-vaccinated against influenza (supplementary table S5 ).

COVID-19 patients had longer hospital and ICU stays. Critical care costs for COVID-19 patients were almost twice those associated with influenza patients, with a median difference of 9,268 euros between groups (p<0.001) ( Table 4) . COVID-19 was independently associated with higher costs of critical care, pharmaceutical treatment, and complementary tests (supplementary Table S6 and S7).

The present study details clinical characteristics, outcomes, and resource consumption of patients hospitalized for COVID-19 or influenza requiring supplemental oxygen on admission.

COVID-19 patients were younger and healthier than those with influenza, as previously reported [4,6,16-18,22], with consistent differences in rates of smoking, hypertension, pneumopathy, heart failure, and renal disease. Since many patients with pneumopathy were treated with

corticoid therapy, immunosuppression was especially high in the influenza group. COVID-19

individuals however tended to have higher BMIs [4].

Whereas COVID-19 cases had more general symptoms, dyspnea and ARDS were more seen in influenza patients at baseline. In contrast, COVID-19 cases were more likely to worse during admission. These findings describe the natural history of some COVID-19 cases, who develop respiratory deterioration during the inflammatory stage of the disease [29].

As previously reported, bacterial pulmonary coinfections were uncommon in COVID-19 at baseline [30] , which contrasts with previous data from influenza epidemics [31] . Conversely, hospital-acquired infections were more frequent with COVID-19 due to longer hospital and ICU stays.

Concerning outcomes, mortality was three times higher for COVID-19 than influenza, which coincides with previous data [4-6,8,20]. Our data suggest that mortality was especially high among older patients (≥74-years) with COVID-19, which reinforces previous evidence [10] identifying age as a key factor in COVID-19 outcomes. Due to the limited number of observations for younger individuals, the burden of influenza and COVID-19 on younger cohorts warrants further investigation. COVID-19 cases had more frequently pneumonia and bilateral involvement. Prior studies have shown that COVID-19 typically follows a peripheral bilateral pattern, with a predominance of ground-glass, linear opacities or consolidations depending on the stage of the disease [32].

Although bilateral pattern is frequent in influenza, prior series have also found lower rates of bilateral involvement [33].

Most non-surviving cases had pneumonia on chest X-ray. In our cohort, 40% of influenza cases baseline X-rays did not show viral pneumonia. Previous studies [34] show computed tomography (CT) scan is the "gold standard" for detection of pneumonia, since lung opacities

12 are visible on CT scan when X-rays are normal. In one study [35] , the proportion of influenza pneumonia increased from 7% to 72% when CT scan was performed. It can be inferred that a pneumonia diagnosis may be missed using X-rays alone.

Moreover, in clinical practice, clinical and radiographic overlap may make it difficult to differentiate between viral pneumonia and acute exacerbations of chronic pulmonary disease or congestive heart failure [36,37].

To explore the impact of radiological findings on outcome, pneumonia was forced into multivariate models of mortality and subgroup analyses were performed. In all settings, COVID-19 outcomes were worse. Excess mortality may be due to increased intrinsic severity in COVID-19, and not only exacerbation of chronic conditions or presence of pneumonia.

None of the COVID-19 patients were immunized during the study period, which contrasts with 17% of vaccinated influenza patients. Subgroup analysis excluding vaccinated influenza patients did not show different trends.

Therapeutic management may also have affected outcomes. Almost the whole influenza cohort received oseltamivir, whereas remdesivir was administered in just 1% of COVID-19 cases.

Furthermore, almost 40% of COVID-19 patients did not receive corticosteroids. While current evidence supports corticosteroid therapy in COVID-19 cases [38], its administration was controversial during the study period [39] . To explore the effect of treatment on outcome, corticosteroids and antiviral treatment were entered as covariates in multivariate analysis. Antiviral treatment was removed from the final model due to the lack of significant differences.

Since we included three seasonal influenza outbreaks (2017-2019), the differences in mortality are unlikely to be the result of an unusually mild influenza season. Of note, it was necessary to review almost three periods of seasonal influenza versus two months of COVID-19 to reach the attempted sample size, reflecting the huge influx of patients in our institution during the first

wave of the COVID-19 pandemic. It may be inferred that the sudden demand for hospital resources may have negatively affected care of COVID-19 cases.

Our findings on resource consumption show that patients with SARS-COV-2 more frequently received respiratory support, were almost three times more likely to be admitted to the ICU and had longer hospital and ICU stays. The costs of critical care, pharmaceutical treatment and complementary tests were also higher in the COVID-19 group. While previous studies [4-6,8,16,18] have found that COVID-19 patients consume more resources in terms of hospital stay and ICU bed occupancy, this is to our knowledge the first to detail those costs.

Our study has the limitations of a retrospective, single-center study. No genotyping studies were conducted due to the timing of study data collection, although it is highly likely that COVID-19 patients were affected by wild-type B.1. These results may not therefore reflect the current scenario, in which multiple SARS-CoV-2 variants are circulating globally. Likewise, the absence of vaccinated COVID-19 patients during the study period may not reflect the current profile of inpatients with COVID-19. Second, patients with COVID-19 and seasonal influenza cannot be compared directly because the cohorts come from different time periods. Third, many influenza cases did not present pneumonia on admission. Even though CT is considered the gold standard for detecting pneumonia, pulmonary X-ray findings could have been considered an additional inclusion criterion. Fourth, antiviral was used for the influenza group, for which studies have shown a decrease in mortality [40] . In contrast, for patients with COVID-19 there was no effective antiviral therapy. Fifth, during the first wave of the pandemic, SARS-CoV-2 detection was occasionally performed alone. Nevertheless, it is unlikely that influenza co-infections were missed in our study because of the study timing. Finally, considerable effort was made to fully adjust for a few covariates; nevertheless, the overall number of events was low, which limits the precision of some estimates, particularly for important subgroups. We did not include interesting laboratory parameters such as ferritin, d-dimer, or interleukin-6 in multivariable models because Funding: This study was carried out as part of our routine work. Variables explored in the initial multivariate model: group (COVID-19 or influenza), sex, age, Charlson comorbidity index, current smoker, hypertension, dyslipidemia, BMI, baseline PaO2/FiO2, baseline MEWS, bilateral involvement, antiviral and corticosteroid therapy. Bilateral involvement was forced into the model. 

A Novel Coronavirus from Patients with Pneumonia in Table 4. Univariate analysis of healthcare resource consumption and economic impact for Influenza and COVID-19 patients in the overall cohort and in the pneumonia subgroup